Amelioration of cognitive deficit in schizophrenia Mental and Behavioural Disorders Schizophrenia
Conditions
Interventions
Patients included in the study will be examined by RBANS to determine cognitive deficit and the current symptom severity is assessed by psychiatric scale (PANSS) at the beginning of the study. Patient
Sponsors
National Institute of Mental Health
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male and female inpatients or outpatients aged 18-50 years 2. Meet ICD-10 criteria for schizophrenia (F20) 3. The mental ability to understand and sign the Informed Consent Form 4. Being on a stable and adequate dose of antipsychotics (monotherapy or combination) for at least two weeks before enrollment and if clinically appropriate to continue on an unchanged dose of antipsychotics during the trial 5. The score for mildly to moderately ill patients in the Positive and Negative Syndrome Scale (PANSS </= 75) at the initial visit
Exclusion criteria
Exclusion criteria: 1. Psychiatric comorbidity on axis I and II according to DSM V in the 6 months before enrollment to the study 2. Contraindications of tDCS (skin disease, superficial injury and fracture or infraction of skull in the stimulation area, epilepsy, metallic plates in the head) 3. Inadequate treatment of psychosis according to recommended guidelines (duration, dose) 4. Pregnancy or breastfeeding 5. Patients with severe and/or unstable somatic disorders (cardiovascular, disease, neoplasms, endocrinology disorders etc) 6. Patients treated with electroconvulsive therapy less than 3 months before enrollment or suffering from neurological disorder (e.g. epilepsy, head trauma with loss of consciousness) 7. Substantial suicidal risk as judged by the treating psychiatrist 8. History of substance-induced disorders in the last year except for nicotine dependency 9. Sensory and motor impairment precluding the participation in CT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive functions assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline, 1-week endpoint and 3-week endpoint | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom severity measured by the Positive and Negative Syndrome Scale (PANSS) at baseline, 1-week endpoint and 3-week endpoint | — |
Countries
Czech Republic
Outcome results
None listed